- Categories: Pipeline
- Time of issue:2018-01-24 00:00:00
MabSpace has established a pipeline of therapeutic antibodies targeting various compoents of the tumor microenvironment. The lead asset is a second generation blocking PD-L1 ab with unique pH-dependent antigen binding and recycling properties. To enable combination therapy, MabSpace has developed antibodies targeting angiogeneic receptor VEGFR2, agonist antibody targeting OX40 for enhancing T cell activities and suppressing regulatory T cells, as well as antibody targeting CSF1R for the inhibition of immune suppresiion mediated by tumor associated macrophage. In addition, MabSpace has ongoing projects targeting dendritic cells and other checkpoint inhibitors.
Scan the QR code to read on your phone